Drug | Target | Company | Indication |
---|---|---|---|
Avastin (Bevacizumab) | VEGF | Genentech | mCRC, NSCLC, Advanced breast cancer |
Erbitux (Cetuximab) | EGFR | Imclone | mCRC & Head and Neck cancer |
Vectibix (Panitumumab) | EGFR | Amgen | mCRC |
Lucentis (Ranibizumab) | VEGF | Genentech | Wet Age-related macular regeneration |
Macugen (Pegaptanib) | VEGF | OSI Pharmaceuticals | Wet Age-related macular regeneration |
Endostar (Endostatin) | Angiogenesis inhibitor | Shangdong Simcere Medgen | Lung cancer |
Sorafenib (Nexavar) | VEGFR, PDGFR & Raf | Bayer AG/Onyx | Advanced RCC |
Sunitinib (Sutent) | VEGFR, PDGFR & c-kit | Pfizer | Advanced RCC & GIST |
Thalomid (Thalidomide) | Angiogenesis inhibitor | Celgene Corporation | Multiple Myeloma |
Sorafenib (Nexavar) | VEGFR, PDGFR & c-kit | Bayer AG/Onyx | Advanced RCC |
Sunitinib (Sutent) | PDGFR & VEGFR | Pfizer | Advanced RCC & GIST |
Dasatinib (Sprycel) | Bcr-Abl & Src | Bristol-Myers Squibb | Gleevec-resistant CML or Ph+ ALL |
Lapatinib (Tykerb) | EGFR & Her2/neu | GlaxoSmithKline | Advanced metastatic Her2+ breast cancer |
Velcade (Bortezomib) | Proteosome inhibitor | Millenium Pharmaceuticals | Multiple myeloma |
Tarceva (Erlotinib) | EGFR | Genentech/OSI | Lung cancer |